Beverley E. Pearson Murphy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Beverley E. Pearson Murphy has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
A Missagh Ghadirian
Professor, Department of Psychiatry, McGill University, Montreal, Quebec
1 shared publicationCyndie M. Allison
Psychoendocrinology Unit, Allan Memorial Institute, Montreal, Canada H3A 1A1
1 shared publicationVeena Dhar
Research Assistant, Psychoendocrinology Unit, McGill University, Montreal, Quebec; presently Private Practitioner, Monroeville, PA
1 shared publication
Latest Publications
- 1 October 2000
- Published by Elsevier in The Journal of Steroid Biochemistry and Molecular Biology
- Vol. 74 (3) , 137-142
Determination of progesterone and some of its neuroactive ring A-reduced metabolites in human serum
- 1 October 2000
- Published by Elsevier in The Journal of Steroid Biochemistry and Molecular Biology
- Vol. 74 (3) , 137-142
Determination of progesterone and some of its neuroactive ring A-reduced metabolites in human serum
- Open Access
- 1 April 1998
- Published by SAGE Publications in The Canadian Journal of Psychiatry
- Vol. 43 (3) , 279-286
Neuroendocrine Responses to Inhibitors of Steroid Biosynthesis in Patients with Major Depression Resistant to Antidepressant Therapy
Objective: Patients with major depression frequently have high Cortisol levels and resistance to dexamethasone. We sought to determine to what extent major depression might be influenced by inhibitors of steroid biosynthesis and to study the endocrine changes produced. Method: After drug washout, 20 treatment-resistant patients with major depression were given aminoglutethimide, metyrapone, and/or ketoconazole, along with a small dose of cortisol for 8 weeks. Hamilton Depression Rating Scale (HDRS) ratings, 8:00 AM Cortisol, dehydroepiandrosterone sulfate (DHAS), adrenocorticotropin (ACTH), and testosterone levels were followed weekly or offener. A dexamethasone suppression test (DST) was conducted before and after treatment. Results: Seventeen patients (85%) completed the course of treatment, and a significant mean drop (P ≤ 0.0001) of 50% in the HDRS score occurred by 7 weeks of treatment. Cortisol levels fluctuated widely and were often still high after the patient had improved clinically. Dehydroepiandrosterone sulfate levels fell more uniformly and were found to be a useful indicator of compliance and, to some extent, efficacy with aminoglutethimide and ketoconazole therapy. The correlation between DHAS and HDRS (r = 0.94) was significant (P = 0.02). Testosterone levels in men fell with ketoconazole but returned promptly to normal at the end of treatment. Adrenocorticotropin levels were normal or elevated, depending on the assay used, and rose (P = 0.07; n = 13) in most subjects during therapy. Of the 6 responders who had nonsuppressor DSTs before starting therapy, 5 had reverted to normal 1 to 2 weeks following cessation of therapy (P = 0.0006). Conclusions: Abnormal metabolism of adrenocortical steroids may perpetuate depression, and alterations of synthesis or metabolism of these steroids may lead to a remission.
- 1 April 1998
- Published by SAGE Publications in The Canadian Journal of Psychiatry
- Vol. 43 (3) , 279-286
Open AccessNeuroendocrine Responses to Inhibitors of Steroid Biosynthesis in Patients with Major Depression Resistant to Antidepressant Therapy
Objective: Patients with major depression frequently have high Cortisol levels and resistance to dexamethasone. We sought to determine to what extent major depression might be influenced by inhibitors of steroid biosynthesis and to study the endocrine changes produced. Method: After drug washout, 20 treatment-resistant patients with major depression were given aminoglutethimide, metyrapone, and/or ketoconazole, along with a small dose of cortisol for 8 weeks. Hamilton Depression Rating Scale (HDRS) ratings, 8:00 AM Cortisol, dehydroepiandrosterone sulfate (DHAS), adrenocorticotropin (ACTH), and testosterone levels were followed weekly or offener. A dexamethasone suppression test (DST) was conducted before and after treatment. Results: Seventeen patients (85%) completed the course of treatment, and a significant mean drop (P ≤ 0.0001) of 50% in the HDRS score occurred by 7 weeks of treatment. Cortisol levels fluctuated widely and were often still high after the patient had improved clinically. Dehydroepiandrosterone sulfate levels fell more uniformly and were found to be a useful indicator of compliance and, to some extent, efficacy with aminoglutethimide and ketoconazole therapy. The correlation between DHAS and HDRS (r = 0.94) was significant (P = 0.02). Testosterone levels in men fell with ketoconazole but returned promptly to normal at the end of treatment. Adrenocorticotropin levels were normal or elevated, depending on the assay used, and rose (P = 0.07; n = 13) in most subjects during therapy. Of the 6 responders who had nonsuppressor DSTs before starting therapy, 5 had reverted to normal 1 to 2 weeks following cessation of therapy (P = 0.0006). Conclusions: Abnormal metabolism of adrenocortical steroids may perpetuate depression, and alterations of synthesis or metabolism of these steroids may lead to a remission.